Purpose The ferret cisplatin emesis model has been used for »30 years and enabled identiWcation of clinically used anti-emetics. We provide an objective assessment of this model including eYcacy of 5-HT 3 receptor antagonists to assess its translational validity. Methods A systematic review identiWed available evidence and was used to perform meta-analyses. Results Of 182 potentially relevant publications, 115 reported cisplatin-induced emesis in ferrets and 68 were included in the analysis. The majority (n = 53) used a 10 mg kg ¡1 dose to induce acute emesis, which peaked after 2 h. More recent studies (n = 11) also used 5 mg kg ¡1 , which induced a biphasic response peaking at 12 h and 48 h. Overall, 5-HT 3 receptor antagonists reduced cisplatin (5 mg kg ¡1 ) emesis by 68% (45-91%) during the acute phase (day 1) and by 67% (48-86%) and 53% (38-68%, all P < 0.001), during the delayed phase (days 2, 3). In an analysis focused on the acute phase, the eYcacy of ondansetron was dependent on the dosage and observation period but not on the dose of cisplatin. Conclusion Our analysis enabled novel Wndings to be extracted from the literature including factors which may impact on the applicability of preclinical results to humans. It reveals that the eYcacy of ondansetron is similar against low and high doses of cisplatin. Additionally, we showed that 5-HT 3 receptor antagonists have a similar eYcacy during acute and delayed emesis, which provides a novel insight into the pharmacology of delayed emesis in the ferret.
Introduction
It is generally accepted that nausea and vomiting (emesis) are components of a protective mechanism by which the human body defends itself against ingested toxins. However, the emetic reXex can be triggered inappropriately, and nausea and vomiting are also relatively common side eVects of drugs in current use (e.g. morphine, anti-cancer chemotherapy) as well as dose-limiting toxicities, which may limit the development of novel chemical entities intended for the treatment of a range of diseases (e.g. phosphodiesterase-IV inhibitors for the treatment of asthma [135] ). The multi-system nature of the emetic reXex coordinated in the brainstem and the behavioural and sensory expression of nausea have meant that, to date, preclinical studies of the mechanisms involved and identiWcation of novel anti-emetic agents have involved studies in whole animals (conscious, anaesthetised or decerebrate) [61] . Nausea and vomiting are particularly associated with the treatment of cancer by cytotoxic drugs (e.g. cisplatin), symptoms which patients Wnd particularly distressing and impact upon compliance with treatment. In the absence of anti-emetic prophylaxis, cisplatin induces nausea and vomiting in virtually all patients [109] ; the emetic response lasts up to 5 days on each cycle and is characterised by an intense acute phase lasting »24 h and a less intense but more protracted delayed phase peaking during the period 48-72 h following the administration of cisplatin [72] . In the early 1980s, the ferret (Mustela putorius furo L.) was reported to develop an acute emetic response to high-dose cisplatin (8-10 mg kg ¡1 ) and was proposed as an alternative model to the dog, cat and monkey (commonly used at the time) to study cytotoxic drug-induced emesis and identify potential anti-emetic agents [40] . Subsequently, the acute cisplatin model was modiWed and the dose of cisplatin lowered to 5 mg kg ¡1 to investigate delayed emesis [114] . The ferret model of cisplatin-induced emesis was rapidly adopted for the investigation of new anti-emetic agents and was pivotal in establishing the anti-emetic eYcacy of 5-hydroxytryptamine 3 (5-HT 3 ) [94] and tachykinin NK 1 receptor antagonists [148] , which are both currently in widespread use for the treatment of chemotherapy-induced nausea and vomiting [109] .
The use and beneWt of animal models in research is regularly questioned and anecdotal evidence or unsupported claims, as opposed to quantitative support, are too often used as justiWcations [88, 105] . There has recently been a growing interest in systematic reviews and meta-analyses to assess the validity of animal models (i.e. how preclinical research has informed clinical research) and their utility in drug discovery (i.e. evaluate data and inform the decision to carry out a clinical trial). The NuYeld Council for Bioethics [101] recommends that such reviews are undertaken to "evaluate more fully the predictability and transferability of animal models". Such analyses also have implications for the application of the principles of the 3Rs (Replacement, ReWnement, Reduction) to animal experimentation [61, 68] and should inform preclinical guidelines produced by regulators (e.g. [37] ). Recently, systematic reviews and meta-analysis of animal models of stroke have been carried out. A retrospective study concluded that even though individual studies had reported beneWcial eVects of the calcium channel blocker nimodipine; overall, the preclinical data available were not conclusive [62] , which is consistent with the fact that this type of drug was without eVect in humans [63] and highlights the necessity of quantifying animal data adequately before starting clinical trials. Later studies assessed the preclinical evidence of the eVect of potential treatments in experimental stroke and characterised their neuroprotective properties in order to identify research priorities [78] [79] [80] .
The cisplatin-induced emesis ferret models provide a unique opportunity to assess the value of systematic reviews in speciWc areas, because the wealth of data available in this relatively circumscribed area allows assessment of two characteristics of a model: the response to cisplatin itself, and the anti-emetic potential of agents that are currently used in humans. The aim of this systematic review is twofold: Wrstly, this study intends to provide an objective measure of the characteristics of cisplatin-induced emesis in the ferret, in terms of the latency, magnitude (number of retches and vomits) and proWle of the emetic response. Secondly, the eVect of 5-HT 3 receptor antagonists in the ferret model will be quantiWed; the present study will assess the eYcacy of ondansetron against the acute phase of emesis; additionally, we will compare the overall eVect of 5-HT 3 receptors antagonists against the acute and delayed phases of emesis.
This paper is the Wrst systematic review and meta-analysis covering a model of emesis and anti-emetics. It provides evidence, which supports the predictability of the model and identiWes new features of the model not apparent from individual studies. Additionally, it shows the limitations of the model and identiWes opportunities for enhanced animal welfare according to the principles of the "3Rs" formulated by Russell and Burch over 50 years ago [126] .
Methods

Search strategy
Studies were identiWed from Pubmed (1974 to March 2007) and Embase (1980 to March 2007) using the combination of words: CISPLATIN and FERRET; hand searching of abstracts of scientiWc meetings and personal Wles. All references of newly identiWed publications were also screened until no further eligible references were found. Language was not restricted. Values for data expressed graphically were either requested from authors or measured from the graphs. Corresponding authors were also contacted to obtain data that was not reported clearly enough in their publications.
Inclusion criteria:
• Report of cisplatin-induced emesis in the ferret • Emetic response documented, and quantiWed by at least one of the following: latency to onset of emesis (retching or vomiting), number of animals developing emesis, number of retches (R), vomits (V), retches and vomits (R+V) deWned according to our deWnition and reported as mean only or mean § SEM or SD, and number of ferrets per group.
Exclusion criteria:
• Number of animals not stated • Emetic response investigated under anaesthesia • Emetic response not reported as the number of animals developing emesis, or mean latency, or mean number of retches and vomits compatible with the standard deWnition of emesis.
Emesis was deWned as retching (i.e. rhythmic abdominal contractions against a closed glottis) and vomiting (i.e. rhythmic abdominal contractions associated with the oral expulsion of solid or liquid materials from the gastrointestinal tract) [14, 22, 89] . Reports stating this deWnition in their methods section were included in this study; if the deWnition was absent or unclear, evaluation of the results reported and their inclusion in this quantitative review were left to the judgement of the investigator and discussed with co-workers; reports were included:
• If the same team had published other reports clearly stating this deWnition or a member of the team-most senior or corresponding author-was contacted to conWrm the deWnition used to characterise emesis • If the report referred to publications clearly stating this deWnition • If the deWnition stated allowed the identiWcation of the number of retches and/or vomits according to our deWnition.
The latency (time to onset of emesis) was a potential confounding factor as many publications reported the latency as a mean for all the animals in the groups, including those free of emesis, in which case the latency was taken as the total duration of the observation time. All latencies were recalculated as the mean latency to the Wrst retch or vomit in animals that developed emesis only. The latency was either measured as the time to the Wrst retch, the time to the Wrst vomit or the time to the Wrst emetic episode. All the latencies reported were included combined together, as it was considered that only a minimal period of time separates the Wrst retch from the Wrst vomit [144] , a more rigid approach including only the studies with either one or the other measurement and excluding those reporting the latency to the Wrst emesis or emetic episode would have induced a greater error.
Data extraction and analysis
Meta-analysis: the ferret model of cisplatin-induced emesis
The number of retches (R), vomits (V), retches + vomits (R+V) and/or latency data from control groups (i.e. animals that received no other drug than cisplatin or cisplatin and an inactive-i.e. non-emetogenic-vehicle) were extracted as mean, standard deviations (SD) and number of animals per group. Weighted mean and weighted mean of the SD were calculated and a one-way ANOVA was carried out to compare the onset of emesis following diVerent doses of cisplatin. Unless stated, all results are reported as mean § SD. In order to identify variables modulating the emetic response, subgroup analyses were carried out according to criteria such as the vehicle used, duration of the observation period, the mode of administration of cisplatin (i.v. or i.p.), the use of anaesthesia and the recovery time prior to the emetic challenge, the strain (Wtch or albino), sex and origin of the ferrets. This analysis was only carried out on the most common doses of cisplatin used to induce acute (10 mg kg
¡1
) and acute and delayed emesis in the ferret (5 mg kg ¡1 ); the two doses were treated separately. Weighted means and the weighted mean of the SDs were calculated and proWles of emesis were constructed with Graphpad Prism ® version 5.0, Graphpad Software Inc., San Diego, USA. DiVerences were assessed by a one-way analysis of variance (ANOVA) or independent sample t tests as appropriate. Descriptive statistics and comparisons were carried out using SPSS ® 14.00, SPSS Inc., Chicago, USA and CLINSTAT (M. Bland). DiVerences were considered statistically signiWcant when P < 0.05.
Meta-analysis: the eVect of anti-emetics
For the meta-analysis of the eVects of anti-emetics, comparisons were only included if the eVect of a prophylactic antiemetic treatment was reported, the 3 outcomes measured were: the number of R+V, proportion of animals experiencing emesis and latency to the onset of emesis. To calculate the eVect size and its 95% conWdence interval for the continuous outcomes (i.e. R+V and latency), the mean outcome for the treatment group, and the SDs in treatment and control groups were expressed as a proportion of the outcome in the control group [80] . Actual data were used for dichotomous outcomes (i.e. the number of animals with emesis). When a control group was used to assess more than one treatment group, the number of animals in the control group was divided by the number of treatment groups and if needed, adjusted to the next integer. This methodology is consistent with what has been done in another metaanalysis of animal data in a model of stroke [80] . The eVect of ondansetron was examined for each of the 3 outcomes; subgroup analyses were carried out depending on the dose of cisplatin and duration of the observation period, dose, timing and mode of administration of ondansetron, mode of administration of cisplatin, origin of the ferrets, and quality score of the study. Additional analyses examined the eVects of 5-HT 3 receptor antagonists on the latency to the onset of cisplatin (10 mg kg ¡1 )-induced emesis and on the acute and delayed R+V induced by 5 mg kg ¡1 cisplatin (criteria for variation: individual compound). In the later analysis, comparisons on a given day were only included if the antiemetic treatment started before or at the start of the 24-h period and was continued throughout the day.
Methodological quality of individual studies was assessed according to criteria chosen to evaluate the reliability of the data extracted. These criteria were: no duplicate publication identiWed-conWrmed or suspected-, retch and vomit clearly deWned or deWnition conWrmed by authors, latency to the Wrst retch or vomit given, SEM/SD given for the mean latency, number of retches and vomits or R+V given, SEM/SD given for the mean R+V, number of ferrets completely protected given (1 point per criterion fulWlled), origin, sex, strain and body weight of the ferrets given (1/2 point per criterion fulWlled). Each study was given a quality score out of a possible total of 9 points. The DerSimonian and Laird method was used to combine dichotomous (risk diVerence [RD] ) and continuous data (weighted mean diVerence [WMD] ). The random-eVects model was chosen over the Wxed eVect assumption because it incorporates inter-study diVerences into the analysis of the overall treatment eYcacy [28] . The data were analysed with Review Manager (RevMan. Version 5.0 for Macintosh. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008). All eVect estimates are reported as mean and 95% conWdence intervals. Z tests were used to assess the overall eVect of treatments and Chisquared ( 2 ) tests were used to assess the heterogeneity along with I 2 , which describes the percentage of the variability in eVect estimates that is due to heterogeneity rather than chance (a value greater than 50% may be considered substantial heterogeneity). The diVerences between the treatment eVects of sub-categories of a particular outcome were assessed by a Z test [1, 87] , potential publication biases were assessed by Funnel plots [143] . 
Anti-emetic drugs examined
Ondansetron: 9-methyl-3-[(2-methylimidazol-1-yl)methyl]- 2,3-dihydro-1H-carbazol-4-one. Granisetron: 1-methyl-N- (9-methyl-9-azabicyclo[3.3.1]nonan-7-yl)indazole-3-car- boxamide. Indisetron: N-(3,9-dimethyl-3,9-diazabicy- clo[3.3.1]nonan-7-yl)-1H-indazole-3-carboxamide. Zacopride: 4-amino-N-(1-azabicyclo[2.2.2]octan-8-yl)-5- chloro-2-methoxybenzamide. FK1052: (7S)-10-methyl-7- [(5-methyl-1H-imidazol-4-yl)methyl]-8,9-dihydro-7H-pyr- ido[1,2-a]indol
Results
Publications
As of March 2007, 182 publications were retrieved, 115 publications describing cisplatin-induced emesis in the ferret were identiWed, 32 publications were excluded and 83 publication contained usable data ( Fig. 1; Tables 1, 2) . A further 15 publications were excluded on the grounds that data was already reported elsewhere. The remaining 68 publications were either fully or partly included as some papers presented original data and duplicate data together, in this case only the original data was extracted and the duplicate data was ignored.
Out of the 68 publications from which at least one outcome was extracted, 44, 10 and 9 publications reported the eVect of at least one 5-HT 3 , NK 1 receptor antagonist and [97] glucocorticoid, respectively. In terms of outcome, 63 studies reported the latency, which was either measured as the latency to the Wrst retch (13% of the publications reporting the latency), the latency to the Wrst vomit (16%) or the latency to the Wrst emetic episode (75%). Fifty-one studies reported the number of retches and vomits (R+V) in a given observation time, 37 and 36 studies respectively reported the number of retches and vomits separately. The number of animals with emesis during the duration of the observation time was reported in 45 publications. 
Meta-analysis: the ferret model of cisplatin induced emesis
Dose of cisplatin
The latency to the onset of emesis was dose dependant; the time of onset was signiWcantly delayed following a dose of cisplatin of 5 mg kg
¡1
, compared with higher doses (6-20 mg kg ¡1 , one-way ANOVA followed by Bonferroni post-tests, see Fig. 2 ). Additionally, diVerences between the doses of 6-20 mg kg ¡1 were detected (P < 0.001, one way ANOVA) and the latency shortened when the dose increased.
The 10 mg kg
¡1 cisplatin model
The duration of the observation period varied from 2 to 40 h (at which time the animals were killed). The most common observation period was 4 h, during which 107 § 48 R+V (n = 199, 22 studies) were observed. In studies using 2, 3, 6, 24 and 40 h observation periods, 79 § 35 R+V (n = 40, 6 studies), 101 § 48 R+V (n = 29, 3 studies), 170 § 56 R+V (n = 73, 8 studies), 204 § 52 R+V (n = 16, 3 studies) and 188 R+V (n = 4, 1 study) were observed, respectively. The number of R+V signiWcantly increased as the observation period increased up to 24 h (one-way ANOVA, P < 0.001). The intensity of emesis reached a maximum after 2 h and decreased to a very low level (less that 5 R+V per hour) from 3 h onward post cisplatin (Fig. 3a) .
The latency to the onset of emesis was shorter when cisplatin was administered intravenously (1.16 § 0.35 h, n = 277) compared to intraperitoneally (1.51 § 0.29 h, n = 134, P < 0.001, independent sample t test). However, the route of administration was directly related to the use of anaesthesia, and all the animals injected with cisplatin DiVerences between the doses were assessed by one-way ANOVA followed by Bonferroni post-tests, ***p < 0.0001 compared with all other doses in the post-tests. The exact latency values, the number of ferrets from which those values were calculated (n) and the number of studies from which this data was extracted (S) are given above each column intravenously (i.v.) had prior anaesthesia during which an i.v. line was implanted or were anaesthetised at the time of cisplatin injection, and prior anaesthesia was not reported in any of the animals that received an intraperitoneal (i.p.) injection of cisplatin. The recovery period between anaesthesia and the administration of cisplatin did not make a diVerence as ferrets that received cisplatin under anaesthesia developed emesis with a latency of 1.21 § 0.32 h (n = 93), and those allowed up to 3 and more than 3 days recovery developed emesis with a latency of 1.11 § 0.31 h (n = 51) and 1.13 § 0.46 h (n = 89), respectively (one-way ANOVA, P = 0.21). The use of an injectable anaesthetic (sodium pentobarbital 30-35 mg kg ¡1 i.p.) further shortened the latency (0.95 § 0.14 h, n = 46) compared to volatile anaesthetics (1.21 § 0.39 h, n = 176, P < 0.001, independent sample t test).
Intraperitoneal cisplatin induced a more severe emetic response and 156 § 41 R+V (n = 19) and 172 (n = 65, SD not available) were quantiWed over 4 and 6 h, respectively, compared to 102 § 52 R+V (n = 180, P < 0.001, independent sample t test) and 152 (n = 8, SD not available) following i.v. cisplatin injection (with prior anaesthesia). No diVerences were observed over an observation period of 2 h (i.p.: 72 § 41, n = 22; i.v.: 88 § 32, n = 18, P = 0.194, independent samples t test). There was not enough data available on the emetic response quantiWed for 3, 24 and 40 h to investigate the inXuence of the mode of administration of cisplatin and the use of anaesthesia.
In animals that did not receive any vehicle, the latency was 1.39 § 0.20 h (n = 18) and ferrets had 92 § 15 R+V (n = 5). DiVerent vehicles such as saline/distilled water (1.30 § 0.38 h, n = 296; 97 § 31 R+V, n = 125), propylene glycol (1.23 § 0.06 h, n = 4), PEG 300 (1.79 § 0.18 h, n = 5), Tween 80 (1.22 § 0.19 h, n = 8) and methyl cellulose (1.13 § 0.25 h, n = 5) impacted on the latency P < 0.0001, one-way ANOVA) but no signiWcant diVerences were found compared to the group that received no vehicle (P > 0.05, Bonferroni post-tests). Glucose (1.33 § 0.24 h, n = 7; 148 § 100 R+V, n = 7) was also found to increase the number of R+V (P < 0.05, one-way ANOVA and Bonferroni post-tests).
No diVerences were detected in latency or number of R+V over 4 h in groups of male ferrets only compared to groups of males and females (P > 0.05, independent sample t tests). The latency was signiWcantly reduced in albino ferrets (1.07 § 0.14 h, n = 29) compared to Wtch ferrets (1.34 § 0.20 h, n = 70) and mixed groups of albino and Wtch ferrets (1.25 § 0.36 h, n = 108, P < 0.05, one-way ANOVA and Bonferroni post-tests) but not enough data were available to compare the number of R+V.
The latency to the onset of emesis was signiWcantly longer in ferrets bred in New Zealand (1.73 § 0.37 h, n = 11) compared to animals bred in the UK (1.25 § 0.44 h, n = 170) and in the USA (1.31 § 0.19 h, n = 176, P < 0.05, one-way ANOVA and Bonferroni post-tests). No diVerences were detected in the number of R+V over 4 h (P > 0.05), but the number of R+V over 2 h was reduced in New Zealand ferrets (40 § 41 R+V, n = 6) compared to U.K. animals (88 § 32 R+V, n = 18, P = 0.007, independent sample t tests). As all the ferrets originating from New Zealand were challenged with an intraperitoneal dose of cisplatin, a sub-analysis was carried out only in animals administered cisplatin i.p. and the delay in latency was still signiWcant in ferrets bred New Zealand compared to animals bred in the UK (1.43 § 0.46 h, n = 29, P < 0.05) but not to animals bred in the USA (1.51 § 0.21 h, n = 84, P > 0.05, one-way ANOVA and Bonferroni post-tests).
The 5 mg kg ¡1 cisplatin model (acute and delayed emesis model)
Fourteen studies investigated cisplatin-induced acute and delayed emesis in the ferret; cisplatin was administered i.p. in all studies and no study reported prior use of anaesthesia. A biphasic proWle of emesis was observed; the acute phase started 10.51 § 0.58 h (n = 156) after cisplatin administration, peaked after 12 h and a nadir was reached after 24 h (Fig. 3b) . The delayed phase was more intense than the acute phase and reached a peak 48 h post cisplatin before gradually decreasing in intensity during the next 24 h, until 72 h post cisplatin, at which time a small amount of emesis still persisted. 105 § 83 R+V (n = 215) and 340 § 171 (n = 153) were observed during the acute and delayed phase, respectively (161 § 98 R+V during day 2 and 179 § 94 R+V during day 3, n = 130). Overall, 448 § 231 R+V (n = 153) were observed during the entire 72-h period.
In animals that did not receive any vehicle, the latency was 11.76 § 9.86 h (n = 98) and animals that received i.p. injections of vehicles such as saline, distilled water and 10% NaHCO 3 Overall, the injection of a vehicle had an impact on the latency (P < 0.0001, one-way ANOVA) but no speciWc diVerences were detected compared to the group that did not receive any vehicle (P > 0.05, Bonferroni post-tests). None of the vehicles had a signiWcant impact on the number of R+V during the acute or the delayed phase (P > 0.05, one-way ANOVA). Neither the strain nor the sex of the ferrets had an impact on the latency or the number of R+V (P > 0.05, one-way ANOVA).
Meta-analysis: the eVect of anti-emetics
EVect of ondansetron on the acute phase of emesis
Outcome: number of retches and vomits (R+V) Data for the number of R+V was extracted from 11 full papers, 23 comparisons involving 107 ferrets assessed the eYcacy of ondansetron versus control during the acute phase of emesis induced by 5 and 10 mg kg ¡1 cisplatin. As shown in Fig. 4 , the overall eVect of ondansetron was a reduction of the R+V by about 70% (¡0.69, ¡0.82 to ¡0.55) and this was highly signiWcant (Z = 10.05, P < 0.0001). A small statistical heterogeneity was detected ( 2 = 37.15, df = 23, P = 0.03; I 2 = 38.1%). Five variants of the acute model of cisplatin-induced emesis were combined in this meta-analysis: emesis induced by 5 mg kg ¡1 cisplatin and R+V quantiWed for 24 h and emesis induced by 10 mg kg ¡1 and R+V quantiWed for 24, 6, 4 and 2 h. Ondansetron signiWcantly reduced the R+V in all variants of the model but one; as shown Table 3 , the reduction of R+V did not reach statistical signiWcance when emesis was induced by 10 mg kg ¡1 cisplatin and quantiWed for 24 h. There was a trend for the eVect of ondansetron to increase with shorter observation times (41, 68, 70 and 93% reduction for 24, 6, 4 and 2-h observation periods, respectively) but this did not reach statistical signiWcance. The R+V reduction was dose-dependent, doses of 1-10 mg kg ¡1 aVorded a more eVective protection than lower doses of 0.1-0.5 mg kg ¡1 (40 and 83%, respectively, Z = 2.52, P = 0.010). The regimen of ondansetron administration did not change the outcome; the eVect of ondansetron was similar with i.v., i.p., and s.c. injections (Z tests, P > 0.05) and ferrets treated 30 min prior to cisplatin administration received the same degree of protection as ferrets treated at the time of cisplatin injection (Z = 0.04, P = 0.965, see Table 3 ). With longer observation periods, ondansetron three times daily was as eVective as twice-daily injections (Z = 0.05, P = 0.959). Ondansetron had the same eYcacy on the R+V induced by an i.p. or an i.v. dose of cisplatin (Z = 1.07, P = 0.287) and the origin of the animals or the quality score of the studies (see Table 1 ) did not inXuence the outcome (Z tests, P > 0.05).
Outcome: number of animals with emesis Data on the number of animals with emesis was extracted from 14 publications; 28 comparisons involving 256 ferrets were identiWed. The global estimate of the eVect of ondansetron was , ondansetron abolished the emetic response during the observation time in one-third of the ferrets (see Fig. 5 ). Overall, this eVect was signiWcant (Z = 4.09, P < 0.001) but a substantial statistical heterogeneity ( 2 = 115.13, df = 27, P < 0.001, I 2 = 76.5%) was detected between comparisons. Subgroup analyses revealed diVerences in estimates of eYcacy between variants of the model. Whereas ondansetron had a signiWcant eVect against emesis induced by 10 mg kg ¡1 cisplatin and quantiWed over short observation times (2-4 h) it did not show any signiWcant eVect against 10 mg kg ¡1 cisplatininduced emesis quantiWed for 6 and 24 h and 5 mg kg ¡1 cisplatin-induced emesis quantiWed for 24 h (see Table 4 ). EYcacy increased as the dose increased, and only doses of ondansetron higher than 0.1 mg kg ¡1 had a signiWcant eVect but there was signiWcant heterogeneity within those two subgroups (see Table 4 ). No statistical diVerences were detected between i.p., i.v. and oral (p.o.) administration of ondansetron (Z tests, P > 0.05) but 2 and I 2 tests revealed a high degree of heterogeneity in all 3 subgroups. Administered s.c., ondansetron was ineVective but this could Table 3 Sensitivity analyses of the eVect of ondansetron on the number of retches + vomits (R+V) induced by cisplatin (5 or 10 mg kg ¡1 )
The eVect estimate was computed as the weighted mean diVerence (WMD) and expressed as the proportion of retches and vomits in the control group. An eVect estimate of ¡1 indicates that emesis was abolished in the treatment group, 0 indicates that the treatment had no eVect on the R+V response and an eVect estimate >0 indicates that the treatment increased the number of R+V. The variables examined were the variant of the cisplatin model (5 or 10 mg kg ¡1 cisplatin and the duration of the observation period), the mode of administration of cisplatin, the dose of ondansetron, the regimen of ondansetron administration (mode of delivery and timing relative to cisplatin administration), the animal origin (country animals were bred) and the quality score assigned to the study where comparisons were extracted potentially be misleading as only 2 comparisons were included in that group and both reported the number of animals completely protected for 24 h in which setting none of the animals were completely protected (see Table 4 , Fig. 5 ).
The regimen used did not inXuence signiWcantly the number of animals completely protected by ondansetron. There were no diVerences between the subgroup that received ondansetron at the time of cisplatin injection and the subgroups that received it 30 min and 1 h prior to cisplatin (Z tests, P > 0.05) but once again, these results should be taken with caution as the heterogeneity within each subgroup was high. With longer observation times (24 h), ondansetron was equally ineVective given 2 or 3 times a day. Ondansetron appeared slightly more eVective when cisplatin was injected i.v. compared to i.p. but this did not reach statistical signiWcance (Z = 1.757, P = 0.079) and could be biased by the fact that in all the comparisons where animals were observed for 24 h, cisplatin was injected i.p. Furthermore, heterogeneity was, once again, highly signiWcant in both groups (see Table 4 ). The origin of the animals and the quality score of the studies did not inXuence the eVect of ondansetron (Z tests, P > 0.05); however heterogeneity was high in all subgroups (see Table 4 ).
Outcome: latency Latency data was extracted from 10 full papers. Fifteen comparisons involving 131 ferrets assessed the eVect of ondansetron on emesis induced by 10 mg kg ¡1 cisplatin and 3 comparisons assessed the eVect of ondansetron on the latency to the onset of emesis induced by 5 mg kg ¡1 cisplatin (see Fig. 6 ). The global estimate of the eVect of ondansetron on the latency was 0.86 (0.49-1.24), which means that the latency was nearly twice as long in the groups treated with ondansetron compared to the control groups. This eVect was signiWcant (Z = 4.45, P < 0.001) but 2 test revealed a high degree of heterogeneity ( 2 = 314.35, df = 14, P < 0.001), which was corroborated by the I 2 (96%). Subgroup analysis revealed that ondansetron statistically delayed the latency to the onset of emesis induced by 10 mg kg ¡1 cisplatin but not 5 mg kg ¡1 cisplatin (Table 5 , Fig. 6 ). The eVect of ondansetron was dose dependant and doses of 1 mg kg ¡1 conferred a signiWcantly higher protection, increasing the latency by about 200% (Z tests, P < 0.05). Ondansetron was more eVective when given i.p. than p.o. or i.v. (Z tests, P < 0.05); however, this result needs to be taken with caution as ondansetron was injected i.p. in all the comparisons where the highest dose was given (see Fig. 6 ). No signiWcant diVerences were observed with diVerent treatment times, there was no diVerence in outcome if cisplatin was injected i.p. or i.v. and the origin of the ferrets did not inXuence the outcome (Z tests, P > 0.05). The outcome was not inXuenced by the quality of the study (see Table 1 ) as no . Point estimates and 95% conWdence intervals for each of the ondansetron versus control comparisons ranked by dose. The eVect estimate was computed as the risk diVerence (RD) and represents the proportion of animals with emesis during the duration of the observation period. An eVect estimate of 0 indicates that the treatment had no eVect on the number of animals with emesis, ¡1 indicates maximal eVect. The size of each square represents the weight of the comparison in the total RD calculation diVerences were detected between studies scoring less than 5 out of 9, between 5 and 7/9 and 7.5 or higher (Z tests, P > 0.05).
Funnel plots for the eVect of ondansetron on the R+V and the number of animals with emesis were relatively symmetrical (see Fig. 7 ). The funnel plot for the latency was slightly asymmetrical, which reXects the high degree of heterogeneity detected for this outcome. Overall, no associations between treatment eVect and sample size were detected, suggesting no evidence of publication bias.
EVect of 5-HT 3 receptor antagonists on the latency to the onset of emesis induced by 10 mg kg
¡1 cisplatin
The eVects of 5-HT 3 receptor antagonists on the latency to the onset of 10 mg/kg cisplatin-induced emesis were Table 4 Sensitivity analyses of the eVect of ondansetron on the number of animals with emesis following the administration of cisplatin (5 or 10 mg kg ¡1 )
The eVect estimate was computed as the risk diVerence (RD) and represents the proportion of animals with emesis during the duration of the observation period. An eVect estimate of 0 indicates that the treatment had no eVect on the number of animals with emesis, ¡1 indicates maximal eVect. The variables examined were the variant of the cisplatin model (5 or 10 mg kg ¡1 cisplatin and the duration of the observation period), the mode of administration of cisplatin, the dose of ondansetron, the regimen of ondansetron administration (mode of delivery and timing relative to cisplatin administration), the animal origin (country animals were bred) and the quality score assigned to the study where comparisons were extracted and Z = 4.44 for day 1, 2 and 3, respectively; P < 0.0001, see Fig. 8 ). There was no diVerence between the eVect of 5-HT 3 receptor antagonists on each of the 3 days (Z tests, P > 0.05); no statistical heterogeneity was detected ( 2 tests, P > 0.05 and I 2 = 0% on each of the 3 days). The eVects of granisetron and ondansetron were signiWcant for each of the 3 days, whereas indisetron did signiWcantly reduce the R+V during day 1 and 3 but not day 2. No signiWcant diVerences were detected between the eVects of ondansetron, granisetron and indisetron for each of the 3 days (Z tests, P > 0.05).
Discussion and conclusions
Cisplatin-induced emesis in the ferret
We found that the latency to the onset of the cisplatininduced emesis was dose dependent, which is consistent with Wndings in other species such as humans [71] , dogs [10] and pigeons [106] . A step-change was observed between 5 and 6 mg kg ¡1 , suggesting a diVerence in the mechanisms triggering emesis at low and high dose, . Point estimates and 95% conWdence intervals for each of the ondansetron versus control comparisons ranked by dose. The eVect estimate is the impact of the treatment on the latency expressed as a proportion of the latency in the control group. An eVect estimate <0 indicates that the latency was shorter in the control group than in the treatment group, 0 indicates that the treatment had no eVect on the latency and an eVect estimate of 1 indicates that the treatment increased the latency by 100%. The size of each square represents the weight of the comparison in the WMD calculation. Note that in 3 comparisons, the eVect estimate was not estimable as only one animal developed emesis in the group treated with ondansetron possibly the activation of an additional mechanism (e.g. recruitment of less sensitive vagal aVerent branches, area postrema). Prior anaesthesia and the route of administration of cisplatin were identiWed as confounding factors; the emetic response was also modulated by some of the vehicles used and factors inherent to the ferrets such as strain and origin. The diVerence between intravenous and intraperitoneal cisplatin may only reXect prior anaesthesia, as these two factors were dependent in the present study. Certainly, anaesthesia had an impact in its own right as diVerences were detected between injectable and volatile anaesthetics. The impact of the ferrets' origin could reXect a genuine diVerence between populations of ferrets but it might also indicate diVerences between laboratories rather than a diVerence between animals; this cannot be determined from the present study.
These Wndings however stress the relevance of choosing appropriate controls (e.g. vehicle control, sham-operated) and homogeneous groups of animals when using the ferret cisplatin model of emesis. Table 5 Sensitivity analyses of the eVect of ondansetron on the latency to the onset of emesis induced by cisplatin (5 or 10 mg kg ¡1 )
The eVect estimate was computed as the weighted mean diVerence (WMD) and represents the impact of the treatment on the latency expressed as a proportion of the latency in the control group. An eVect estimate <0 indicates that the latency was shorter in the control group than in the treatment group, 0 indicates that the treatment had no eVect on the latency and an eVect estimate of 1 indicates that the treatment increased the latency by 100%. The variables examined were the dose and mode of administration of cisplatin, the dose of ondansetron, the regimen of ondansetron administration (mode of delivery and timing relative to cisplatin administration), the animal origin (country animals were bred) and the quality score assigned to the study where comparisons were extracted The proWle of emesis induced by 5 mg kg ¡1 i.p. cisplatin in the ferret was clearly biphasic, which is consistent with the proWle of emesis observed in the clinic [84] but diVerences were observed in the timing and magnitude of the two phases. Whereas the acute phase is more severe than the delayed phase in humans [72, 84] , with an onset 1-6 h following cisplatin infusion [55, 71, 84] , the latency to the onset of the acute phase was greater in the ferret (>10 h) and its relative intensity compared to the delayed phase was lower. The incidence of emesis on each day could not be investigated in the ferret as all reports stated that 100% of the animals developed an emetic response but no distinction was made between the acute and delayed phases. A few studies have however suggested that the acute phase was not observed in all animals [115, 147] , which is also consistent with our recent observations [104] and suggests that whereas the incidence of emesis during the delayed phase is close to 100%, the incidence of acute emesis at this dose is lower. In humans treated with placebo anti-emetics, however, the incidence of emesis during the acute phase (98%, [71] ) is higher than during the delayed phase (44-89% [43, 72] ).
EVect of 5-HT 3 receptor antagonists
The eYcacy of ondansetron in the acute model of cisplatininduced emesis was assessed measuring 3 outcomes: the number of R+V, the number of animals with emesis and the latency to the onset of emesis. Overall, all 3 outcomes permitted the detection of signiWcant anti-emetic protection, which is consistent with Wndings in humans [24] , but diVerent variants of the model resulted in diVerent levels of antiemetic protection. Whereas all variants of the acute model reXected a similar reduction of R+V, ondansetron only delayed signiWcantly the onset of emesis following 10 but not 5 mg kg ¡1 cisplatin, and the number of animals with emesis was only reduced with observation periods no longer than 4 h. In the 10 mg kg ¡1 4 h variant of the model, half of the animals were completely protected from emesis, which was comparable to percentage of patients free of emesis during the acute phase of high-dose (>50 mg m ¡2 ) cisplatin-induced emesis in human patients [58, 65, 85, 124] . Overall, the acute phase of emesis induced by 5 mg kg ¡1 cisplatin represented poorly the clinical situation and the 4 h to 10 mg kg ¡1 model was more predictive of cisplatin-induced emesis in humans.
Overall, 5-HT 3 receptor antagonists reduced the emetic response to the same extent during the acute and delayed phases, which contrasts with Wndings reported in the majority of clinical studies, describing limited or non-signiWcant eVect of 5-HT 3 receptor antagonists during the delayed phase [57, 73] . This discrepancy may be explained by a diVerence in outcome usually measured in humans (daily incidence, percentage of patients developing emesis) and ferrets (severity, number of R+V). Even though daily incidence and severity (measured by visual analogue scale) of the delayed phase emesis appear to be positively correlated in the absence of anti-emetic therapy [72] , they can be uncoupled following anti-emetic treatment and the number of emetic episodes may be reduced while the incidence remains unchanged [100] . Alternatively, it is conceivable that the delayed phase of emesis in the ferret is more sensitive to 5-HT 3 receptor antagonists than it is in humans. The latter would be consistent with a longer acute phase in the ferret (see [110] for details), implying that the mechanism regulating the acute phase (i.e. 5-HT-mediated activation of the abdominal vagal aVerents) remains activated longer. The ferret model thus correctly identiWed the anti-emetic potential of 5-HT 3 receptor antagonists against both the acute and delayed phases of cisplatin-induced emesis, but the magnitude of the anti-emetic eVect during the delayed phase appears greater in the ferret than it is in humans.
Methodology
In the present study, the methodology used in the metaanalysis of human clinical trials was modiWed and adapted to animal research, and several concessions had to be made. First of all, the criteria used to select studies for inclusion into the systematic review and meta-analysis, and assess quality, did not include randomization and blinding. Whereas these two parameters are considered essential for human clinical trials and it has been suggested that their absence favours positive Wndings in animal research [8] , emesis is an objective measurement, which is not investigator-dependent and we have no reason to believe that the inclusion of such studies in our analysis biased our Wndings. Additionally, randomization and blinding in the identiWed studies were too rarely reported to be used as inclusion criteria. The exclusion criteria were chosen to ensure the collection of reliable, clearly deWned data. The majority of excluded studies (see Table 2 ) were removed because emesis was not quantiWed as latency, retches, vomits and/or incidence. We chose not to include outcomes such as "emetic episodes" or "bouts of emesis" in the present analysis because of the disparity of deWnitions and possible interpretations. This may however restrict the conclusions of our study.
Secondly, whereas clinical trials usually report tens or hundreds of patients in each study arm, we found that in the cisplatin ferret model, typically 4 to 8 animals were allocated in each treatment group. This may limit the relevance of such an analysis, designed to compare much bigger samples. Additionally, because a majority of studies compared one control group to several treatment groups-typically diVerent doses of a compound-in order to maintain the data from diVerent doses as distinct comparisons, the number of animals in the control group was divided by the number of treatment groups it was compared to. The limitation of such an approach is that in the eVect estimate calculation, the weight of such comparisons is reduced, which beneWts comparisons extracted from studies that only compared one control group to one treatment group and is not justiWed by the quality of the studies.
Conclusions
We demonstrated the potential of a meta-analysis to address the 3R's (Replacement, ReWnement and Reduction), developed by Russel and Burch as criteria for a humane use of animals in research [126] . By maximising the utilisation of animal data, thus extracting novel scientiWc information without increasing the number of animals, such analysis addresses Reduction, as this reduces the future use of animals. Additionally, the eVects of ondansetron on the 3 outcomes highlighted a logical ReWnement of the model by reducing the observation period. The cisplatin 10 mg/kg to 4 h variant of the model stands out as the most appropriate to study the acute phase of cisplatin-induced emesis, whereas 5 mg/kg to 24-72 h remains the model of choice to study cisplatin-induced delayed emesis.
The present study is a proof of concept. In an attempt to focus the scope of the analysis, it was limited to an animal model with one emetic: cisplatin, one species: the ferret and one class of anti-emetic drugs: 5-HT 3 receptor antagonists; the drugs investigated are already successfully used in humans against chemotherapy-induced emesis. Globally, the eVects in the ferret were consistent with clinical Wndings, which were expected as they were originally developed in the ferret model; this demonstrates that a meta-analysis is an appropriate method to identify the anti-emetic potential of a drug and conWrms that the ferret model of cisplatin-induced emesis is truly predictive and relevant to humans. This method can now be applied to investigate the eVects of NK 1 receptor antagonists, which were also developed using the ferret and which have recently been introduced into the clinic. However, recent studies suggest that there may be a discrepancy between the "broad spectrum" anti-emetic eYcacy in the ferret and the eYcacy in the clinic [3, 25] . This method can also be used in other "model" species (e.g. dog) to reassess "older" compounds such as dopamine receptor antagonists or opioids, whose eVects on cisplatininduced emesis are less well characterised. It can also be directly applied to other emetic models (diVerent emetogen and/or diVerent species) and adapted to assess the relevance of models arguably predictive of nausea and emesis such as pica in the rat and conditioned taste aversion [2, 77] .
